Age Related Macular Degeneration
Conditions
Brief summary
Anti-VEGF intravitreal injections are the treatment of choice in age-related macular degeneration (AMD). However 37% of patients are unresponsive or poorly responsive to these therapies. It is still not possible to foresee the patient's response to anti-VEGF injections. A poor response may be related to an activation of alternative pro-angiogenic pathways with over expression of many other pro-angiogenic cytokines. The primary goal of this study is to measure the aqueous humor concentration of pro-angiogenic cytokines in AMD patients.
Interventions
PROCEDUREAqueous humor samples collection
In addition to the routine examinations performed as part of the usual care of AMD patients, an anterior chamber puncture will be performed to collect the aqueous humor samples.
Sponsors
Centre Hospitalier Universitaire de Nice
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 18 years * Diagnosis of exudative age-related macular degeneration requiring intravitreal anti-VEGF treatment. * Patient for whom the last intravitreal injection of anti-VEGF in the eye is strictly more than 3 months * Signature of informed consent * Affiliation to the French social security system
Exclusion criteria
* Pregnant or nursing patient (a urinary pregnancy test will be performed) * Systemic treatment with anti-VEGF * Intravitreal treatment with anti-VEGF for less than 3 months regardless of the treated eye. * Retinal pathology that can modify the secretion of pro-inflammatory cytokines such as diabetic retinopathy, venous occlusions, intermediate and posterior uveitis. * Diabetes Mellitus * High Myopia * Simultaneous participation in another clinical research protocol in exudative AMD * Person under guardianship, under curatorship, deprived of liberty
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of pro-angiogenic cytokines concentration in the aqueous humor of patients with exudative AMD at 3 months | At Month 3 |
Secondary
| Measure | Time frame |
|---|---|
| Dose of VEGF in the aqueous humor of patients with exudative AMD | At Day 0, Month 1, Month 2, Month 3 |
| Dose of pro inflammatory cytokines in the aqueous humor of patients with exudative AMD | At Day 0, Month 1, Month 2, Month 3 |
| Measurement of visual acuity with Snellen chart | At Day 0, Month 1, Month 2, Month 3 |
| Measurement of visual acuity with ETDRS visual acuity chart | At Day 0, Month 1, Month 2, Month 3 |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORProf. Stéphanie BAILLIF, MD, PhD
Centre Hospitalier Universitaire de Nice
Outcome results
None listed